Back to top
more

Celularity (CELU)

(Delayed Data from NSDQ)

$3.16 USD

3.16
10,536

+0.05 (1.51%)

Updated Aug 23, 2024 03:50 PM ET

After-Market: $3.17 +0.01 (0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CELU

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Celularity, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 0 14 37 0 1
Receivables 12 7 5 0 0
Notes Receivable 0 0 0 0 0
Inventories 6 5 10 0 0
Other Current Assets 2 7 7 0 0
Total Current Assets 20 34 59 0 1
Net Property & Equipment 68 76 91 0 0
Investments & Advances 0 0 0 292 291
Other Non-Current Assets 17 23 3 0 0
Deferred Charges 0 0 0 0 0
Intangibles 18 241 246 0 0
Deposits & Other Assets 10 15 15 0 0
Total Assets 144 401 414 292 292
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 14 6 9 3 0
Current Portion Long-Term Debt 39 38 0 0 0
Current Portion Capital Leases 0 0 3 0 0
Accrued Expenses 11 16 12 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 3 2 2 0 0
Total Current Liabilities 67 62 26 3 0
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 2 2 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 28 0 0
Other Non-Current Liabilities 6 110 259 284 286
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 103 202 315 287 287
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 883 844 763 5 2
Retained Earnings -842 -646 -664 0 3
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 41 199 99 5 5
Total Liabilities & Shareholder's Equity 144 401 414 292 292
Total Common Equity 41 199 99 5 5
Shares Outstanding 19.30 14.80 12.40 3.50 3.50
Book Value Per Share 2.12 13.44 8.02 1.43 1.43

Fiscal Year End for Celularity, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 0 0 3
Receivables NA NA 12 6 5
Notes Receivable NA NA 0 0 0
Inventories NA NA 6 5 6
Other Current Assets NA NA 2 5 4
Total Current Assets NA NA 20 17 18
Net Property & Equipment NA NA 68 71 73
Investments & Advances NA NA 0 0 0
Other Non-Current Assets NA NA 17 25 25
Deferred Charges NA NA 0 0 0
Intangibles NA NA 18 19 102
Deposits & Other Assets NA NA 10 15 15
Total Assets NA NA 144 157 246
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 0 0
Accounts Payable NA NA 14 13 12
Current Portion Long-Term Debt NA NA 39 35 17
Current Portion Capital Leases NA NA 0 0 0
Accrued Expenses NA NA 11 34 33
Income Taxes Payable NA NA 0 0 0
Other Current Liabilities NA NA 3 2 2
Total Current Liabilities NA NA 67 85 65
Mortgages NA NA 0 0 0
Deferred Taxes/Income NA NA 3 3 2
Convertible Debt NA NA 0 0 0
Long-Term Debt NA NA 0 0 17
Non-Current Capital Leases NA NA 0 0 0
Other Non-Current Liabilities NA 6 13 15
Minority Interest (Liabilities) NA NA 0 0 0
Total Liabilities NA NA 103 127 128
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 0 0
Common Stock (Par) NA NA 0 0 0
Capital Surplus NA NA 883 879 874
Retained Earnings NA NA -842 -851 -757
Other Equity NA NA 0 2 2
Treasury Stock NA NA 0 0 0
Total Shareholder's Equity NA NA 41 30 119
Total Liabilities & Shareholder's Equity NA NA 144 157 246
Total Common Equity 0 0 41 30 119
Shares Outstanding 21.90 19.30 19.30 19.30 18.00
Book Value Per Share 0.00 0.00 2.12 1.57 6.58